Core Viewpoint - Baoyi Pharmaceutical-B (02659) has successfully listed its shares at a price of HKD 26.38, raising approximately HKD 922 million, with a significant initial surge of 129.34% to HKD 60.5 per share, indicating strong market interest and investor confidence [1] Company Overview - Baoyi Pharmaceutical is a biotechnology company in the clinical and commercialization stages, focusing on developing and providing recombinant biopharmaceuticals in China using synthetic biology technology [1] - The company targets four independent and high-value therapeutic markets, including large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproductive drugs, and transformative products that replace traditional biochemical products [1] Key Products - Baoyi Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous delivery [1] - The company also offers KJ103, a global first with "best-in-class" potential in low pre-storage antibody and administration frequency for antibody-mediated autoimmune diseases [1] - Additionally, SJ02, a long-acting follicle-stimulating hormone drug for assisted reproduction, has been validated through collaboration [1] - These three core products are in various stages of commercialization, NDA registration, or late clinical phases, indicating a transition from pure R&D to commercialization for Baoyi Pharmaceutical [1]
新股首日 | 宝济药业-B(02659)首挂上市 早盘高开129.34% 旗下三大核心产品即将商业化